Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib

The drug tested in this study is called alisertib. Alisertib is being tested to assess the
effect of a proton pump inhibitor and strong metabolic inducer on the PK of a single 50 mg
dose of alisertib administered as enteric-coated tablets (ECTs).

The study enrolled 55 patients. Participants received either:

- Esomeprazole 40 mg and Alisertib 50 mg

- Rifampin 600 mg and Alisertib 50 mg

All participants were asked to take one tablet of alisertib either once or twice daily in all
cycles. In Cycle 2, participants were asked to take alisertib plus either esomeprazole or
rifampin.

This trial was conducted the United States. The overall time to participate in this study was
10 months. Participants made multiple visits to the clinic plus a final visit, 30 days after
receiving their last dose of study drug for a follow-up assessment.

Inclusion Criteria:

- Male or female participants 18 years or older

- Histologically or cytologically confirmed metastatic and/or advanced solid tumors or
lymphomas

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- Expected survival longer than 3 months from enrollment in the study

- Female participants who are post menopausal, surgically sterile, or agree to practice
2 effective methods of contraception or agree to abstain from heterosexual intercourse

- Male participants who agree to practice effective barrier contraception or agree to
abstain from heterosexual intercourse

Exclusion Criteria:

- Treatment with any anticancer therapy or any investigational agents within 4 weeks
before the first dose of alisertib

- Known hypersensitivity or intolerance to rifampin (for participants considered for
the rifampin drug-drug interaction [DDI] group) or to esomeprazole (for participants
considered for the esomeprazole DDI group)

- Recurrent nausea and/or vomiting within 14 days before the first dose of alisertib,
and known gastrointestinal (GI) abnormality or GI procedure that could interfere with
or modify the oral absorption or tolerance of alisertib

- Participants requiring treatment with clinically significant enzyme inducers within 14
days before the first dose of alisertib and/or requiring the use of these medications
during the study

- A medical condition requiring use of pancreatic enzymes; or daily, chronic, or regular
use of proton pump inhibitors (PPI); or histamine (H2) receptor antagonists

- Participants requiring systemic anticoagulation (excluding low-dose aspirin, or
low-dose anticoagulation to maintain patency of venous access devices).

- Any cardiovascular condition

- Female participants who are lactating or have a positive serum pregnancy test

- Major surgery within the 14 days preceding the first dose of alisertib

- Life-threatening or uncontrolled medical illness unrelated to cancer

- Newly diagnosed or uncontrolled cancer-related central nervous system (CNS) disease

- Autologous stem cell transplant within 3 months

- Prior allogeneic bone marrow or other organ transplantation

- Other severe acute or chronic medical or psychiatric condition

- Known or suspected human immunodeficiency virus (HIV) positive or hepatitis B surface
antigen-positive status, or known or suspected active hepatitis C infection

Please note there are additional inclusion and exclusion criteria. The study center will
determine if you meet all of the criteria.